2/14/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #2 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.

Slides:



Advertisements
Similar presentations
Indicated for Arterial and Venous Embolizations in the Peripheral Vasculature April, 2004.
Advertisements

Pinhas (Peter) Dartal 01 June QA role in development of Percutaneous Aortic Valve prosthesis.
By Justin Martin.  The veins carry oxygen depleted blood back to the heart from the rest of the body.  In the legs, the veins have to fight gravity.
PATENT DUCTUS ARTERIOSUS By: Nicole Stevens. Patent Ductus Arteriosus is a functional connection between the pulmonary artery and the descending aorta.
LOCKOUT/TAGOUT.
2 Heartworms and Heart Murmurs Partnership for Environmental Education and Rural Health Texas A&M University An introduction to problems.
Fatigue Testing: The Effects of Different Surface Treatments on Nitinol Presented by: Lucy Zhu Senior Project: MatE 198B Advisor: Dr. Stacy Gleixner Instructor:
Robotic Needle End Effector for Integration with CT Scan Team Members: David Sun Xuan Truong Chris Willingham Advisor: Dr. Bradford Wood.
The Artificial Heart: A Design Example BIOE 1000 October 18, 2001.
Principal Groups of CHD
CPAP Remote Alarm System BME 272: Oral Report Two Group 15 Kathleen Grunder Jessica Paulsen Molly Rice.
INTRODUCTION A 35 year old woman with transposition of the great arteries repaired with a Mustard procedure attends your clinic for annual follow-up. Her.
Lockout/tagout Authorized employees
Abstract A patient who had transcatheter closure of a large patent ductus arteriosus in early infancy developed aortic coarctation during follow-up. Initially.
3/10/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #3 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.
Vanessa Beretta & Dan Fleming. About CHD A congenital heart defect also known as CHD is a defect in the structure of the heart and great vessels. Most.
Heart Stabilization Device Amir Durrani Ben Hoagland Santosh Tumkur Lucas Burton Advisor: Thomas P. Ryan, Ph.D.
Patent Ductus Arteriosus Occlusion Device David Brogan *, Darci Phillips *, Daniel Schultz *, Dr. Thomas Doyle ‡ * Vanderbilt University Biomedical Engineering.
Improving Field-Induced Magnetic Nanoparticle Drug Delivery BME 273 Group 15 Team Leader : Ashwath Jayagopal (BME, EE, MATH) Members : Sanjay Athavale.
Cardiovascular surgery, Congenital heart disease Dr. Robin Man Karmacharya, Lecturer, Department of Surgery, Dhulikhel Hospital.
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. April 9, 2003.
Patent Ductus Arteriosis (PDA)
Cardiothoracic Surgery. Topics Valvotomy and valve replacement Open heart surgery and cardiac bypass surgery Correction of congenital heart diseases Heart.
CPAP Remote Alarm System BME 272: Oral Report Three Group 15 Kathleen Grunder Jessica Paulsen Molly Rice.
NANS I3 Technology Gaps in Intrathecal Drug Delivery Systems
Field-Induced Magnetic Nanoparticle Drug Delivery BME 273 Group 15 Team Leader : Ashwath Jayagopal (BME, EE, MATH) Members : Sanjay Athavale (BME) and.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
DR AFTAB YUNUS FRCSEd. CHAIRMAN CARDIAC SURGERY
Reptile Anesthesia.  Injectable and inhalant anesthetics are commonly employed both for surgery and sedation for diagnostic or treatment procedures.
Sutureless Percutaneous Anastamosis Device Steve Chen Jamal Siddiqui.
Pulmonary Embolism Extraction Catheter Development Trip Cothren Lauren Nichols Dustin Temple Advised by: Dr. Michael Barnett, VUMC Cardiology.
Patent Ductus and Vascular Occlusion Devices Ornob Roy Elaine Isom Michelle Carlsen Brad Klosterman Advisor: Dr. Thomas Doyle.
Sutureless Percutaneous Anastamosis Device Steve Chen Jamal Siddiqui.
Improving CABG Surgery
THROUGH NERANJAN DHARMADASA JAMES BROWN P09451: Thermo-Electric Module for Large Scale Systems.
Mixing and Injection System for Polyurethane Scaffolds Michael Scherer Dustin Dowell Andrew Solomon February 21 th, 2007.
Patent Ductus and Vascular Occlusion Devices Michelle Carlsen Elaine Isom Brad Klosterman Ornob Roy Advisor: Dr. Thomas Doyle.
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. March 17, 2003.
Patent Ductus Arteriosus (PDA) March of Dimes Fall 2008 November 11, 2008.
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. February 12, 2003.
Patent Ductus and Vascular Occlusion Devices Michelle Carlsen Elaine Isom Brad Klosterman Ornob Roy Advisor: Dr. Thomas Doyle.
Emergency Airways Modification of Transtracheal Jet Ventilation and Retrograde Intubation Techniques BME 272 Senior Design Group 20 Project Undertaken.
Ring Removal Device Team: Evan Rogers, Sujan Bhaheetharan, Tyler Allee, Steve Noel BME 301 February 24, 2006.
Chris Burke, MD. What is the Ductus Arteriosus? Ductus Arteriosus  Allows blood from RV to bypass fetal lungs  Between the main PA (or proximal left.
Congenital Heart Disease
Occlusion Device for Patent Ductus Arteriosus Christina Mathieson & Trung Nguyen Advisor: Dr. Tom Doyle BME 273 – Senior Design Project.
Patent Ductus Arteriosus Occlusion Device Christina Mathieson Trung Nguyen Advisor: Dr. Tom Doyle BME 273 – Senior Design Project.
Common Medical Procedures for Treating Varicose Veins.
Determine method of rapid prototyping or plastic extrusion to create prototype of true-to-scale catheter Determine optimal slot size without affecting.
4/11/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #4 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.
January 26, 2004BME 272/2731 Investigation of Bubble Formation in Tuohy-Borst Adaptors Department of Biomedical Engineering Melanie Bernard, Isaac Clements,
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Further experience with transcatheter closure of.
Improving CABG Surgery
Reptile Anesthesia.
Clinical engineering Lecture (8).
Percutaneous Closure of a Coronary Fistula
Chronic heart failure.
Patent Ductus Arteriosus Occlusion Device
Measuring Neonatal Lung Volume
Converting Elastin-like Polypeptides(ELP) Aggregate to Soluble Form Client: Darin Furgeson PhD School of Pharmacy Dhaval Desai (Leader) Lee Linstroth.
Client: Dr. Jonathan Jaffery Advisor- Brenda Ogle
Improving Coronary Artery Bypass Surgery
Robotic Needle End Arm Effector for Integration With CT Scan
Robotic Needle End Arm Effector for Integration With CT Scan
Improving CABG Surgery
Patent Ductus Arteriosus Occlusion Device Oral Presentation #1
Sutureless Percutaneous Anastamosis Device
Sutureless Percutaneous Anastamosis Device
Fetal Circulation pp
Endoluminal Closure Device
Presentation transcript:

2/14/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #2 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle

2/14/2003 Patent Ductus Arteriosus (PDA)  Ductus arteriosus (DA) allows blood to bypass pulmonary and enter systemic  DA normally closes within hrs of delivery (if not deemed abnormal/patent)  PDA affects 1800 babies/year in USA alone  Many adverse effects  growth retardation, breathlessness or lack of appetite  Most common problem is congestive heart failure

2/14/2003 Current Treatments  Drug therapy (indomethacin)  Implantable devices (most common are coils)  Usually need 3-4 coils  Difficult to remove and reposition  Invasive surgery (ligate the PDA to inhibit blood flow)

2/14/2003 Project Goals  To design, develop and patent a PDA occlusion device that can…  Be delivered via a catheter  Conform to the shape of the PDA and cause occlusion  Can be repositioned easily  Be cost effective (<$200)  Provide an initial success rate of 100%  More patient friendly procedure

2/14/2003 Effect of Occlusion Device

2/14/2003 Our Design

2/14/2003 Delivery Path of Device

2/14/2003 Foam Issues  We can make a polyurethane foam with methylene bisphenyl diisocyanate (MDI), polytetramethylene glycol (PTMEG), 1,4-butanediol and water.  In touch with chemical engineering professors at Vanderbilt.  Also looking to make corporate contacts.

2/14/2003 Work Completed  Conducted extensive research on other treatment methods (to avoid short comings on our design)  Met with Dr. Doyle to discuss our progress and future goals  Locating a company from which to purchase chemicals.  Have ordered Nitinol memory wire in two different diameter thicknesses  Have secured an In-Vitro PDA Simulation device for testing

2/14/2003 Current Status  Making final design refinements to device  Developing life-size PDA device prototype  Developing equations to model PDA testing apparatus  Making arrangements with Mechanical Engineering professor to have Nitinol wire machined here at Vanderbilt  Completing Design Safe and Innovation Work Bench assignments  Making necessary modifications to website

2/14/2003 Needs  Obtain missing foam ingredient (PTMEG)  Make arrangements to machine Nitinol wire  Meet with Dr. Doyle to discuss further progress

2/14/2003 Future Direction  Build scaled prototype with correct biomaterials  Figure out best way to secure Nitinol within device  Begin conducting pressure and durability tests in PDA simulated environment  Refine design based on testing  Talk with Dr. Doyle/Office of Technology Transfer about patenting this PDA Occlusion Device

2/14/2003 Contact Information  David Brogan    Darci Phillips    Daniel Schultz  